Publications by authors named "Stephanie Haiat"
Article Synopsis
- A study assessed the safety and efficacy of gilteritinib in 167 patients with relapsed/refractory FLT3-mutated acute myeloid leukemia (AML), comparing it to data from the ADMIRAL trial.
- The key differences in patient characteristics included higher rates of poor performance status and FLT3-TKD mutations, along with more complex treatment histories among participants.
- The results showed similar rates of complete remission and overall survival between treatment cohorts and highlighted the potential for outpatient treatment benefits for heavily pretreated patients.
The aim of this study was to characterize a large series of 154 patients with acute promyelocytic leukemia (median age, 53 years; range, 18-90 years) and evaluate real-life outcome after up-front treatment with arsenic trioxide and all-trans retinoic acid. All patients were included in the prospective NAPOLEON registry (NCT02192619) between 2013 and 2019. The acute promyelocytic leukemia was de novo in 91% (n=140) and therapy-related in 9% (n=14); 13% (n=20) of the patients were older than 70 years.
View Article and Find Full Text PDFArticle Synopsis
- - A study of 279 hairy-cell leukemia (HCL) patients revealed a median survival of 27 years and a median relapse-free survival of 11 years after first-line treatment with purine analogs (PNAs), mostly cladribine or pentostatin, followed over 10 years.
- - The incidence of relapse was 39% over 10 years, with second-line therapy achieving a median relapse-free survival of 7 years, regardless of whether the same or another PNA was used.
- - Among the patients, 68 second malignancies were identified, showing an increased risk for solid and hematological cancers; however, the use of PNAs was not linked to a higher risk of these additional cancers
Adolescents ALL have a better outcome when treated with pediatric protocol compared to adult protocol. We have tested the feasibility of pediatric protocol to treat 40 consecutive adults ALL. DFS and OS were 73±7%, and 72±7%, and were significantly longer in patients under 40 yo (81±9% vs 51±15%, p=0.
View Article and Find Full Text PDFHistopathological study of bone marrow biopsy (BMB) in chronic myelomonocytic leukemia (CMML) is often difficult and might benefit from an immunohistochemical approach. We immunostained 15 cases of CMML, focusing at two new antibodies staining for CD14 and CD16 on paraffin-embedded tissues. CD68 (KP1), CD68 (PG-M1), and CD163 were not differentially expressed between CMML and chronic myelogenous leukemia (CML).
View Article and Find Full Text PDFWhether rituximab could effectively and safely avoid splenectomy for adults with chronic immune thrombocytopenic purpura (ITP) remains unresolved. A multicenter, prospective, open-label, single-arm, phase 2 trial was conducted to assess rituximab safety and efficacy in adult splenectomy candidates with chronic ITP. Sixty patients with chronic (>or= 6 months) ITP and platelet counts less than 30 x 10(9)/L received a weekly intravenous infusion of rituximab (375 mg/m(2)) for 4 weeks.
View Article and Find Full Text PDFB-cell chronic lymphocytic leukaemia (B-CLL) is the most prevalent leukaemia in Western countries and is characterized by the gradual accumulation in patients of small mature B cells. Since the vast majority of tumoral cells are quiescent, the accumulation mostly results from deficient apoptosis rather than from acute proliferation. Although the phenomenon is relevant in vivo, B-CLL cells die rapidly in vitro as a consequence of apoptosis, suggesting a lack of essential growth factors in the culture medium.
View Article and Find Full Text PDF